Key result
Rare SCN5A variants significantly impacted human NaV1.5 channel function, and lamotrigine altered wild-type but not p.R523C channel inactivation, suggesting increased arrhythmogenic risk in SUDEP.
Why the study?
Rare SCN5A variants have been reported in SUDEP cases, but their impact on cardiac Nav1.5 channel function was unknown.
Rare SCN5A variants found in SUDEP alter cardiac sodium channel function, suggesting an arrhythmogenic mechanism for sudden death in epilepsy that may be modulated by antiseizure medications like lamotrigine.
SCN5A variants may contribute to SUDEP risk via NaV1.5 dysfunction; leaves open gene-specific lamotrigine effects on arrhythmia susceptibility.
Summary Sudden unexpected death in epilepsy (SUDEP) is a leading cause of premature death in epilepsy. The underlying pathological mechanisms are likely to be multifactorial. Cardiac arrhythmia has been suggested as a cause of death in some patients with SUDEP. SCN5A encodes the cardiac Nav1.5 sodium channel. SCN5A variants that result in either loss or gain of channel function cause cardiac arrhythmias. Rare SCN5A variants have been reported in SUDEP cases, but the impact of these variants on channel function is unknown. Here, we use whole‐cell voltage clamp recordings to perform functional analyses of rare SCN5A SUDEP variants, p.V223G, p.I397V, and p.R523C. Expression and biophysical properties, including activation, inactivation, and recovery from inactivation, were probed. Each SCN5A variant significantly impacted human NaV1.5 channel function, indicating that they could cause cardiac arrhythmias. The patient carrying the p.R523C variant was on lamotrigine, an antiseizure medication implicated in SUDEP. Therapeutic concentration of lamotrigine caused a slowing of the rate of recovery from inactivation and a hyperpolarizing shift in the voltage of inactivation of human NaV1.5 wild‐type, but not p.R523C channels, implicating a gene‐by‐drug interaction. These data suggest that SCN5A arrhythmogenic variants may confer increased risk of sudden death in individuals with epilepsy.
No takes yet. Share an insight, caveat, or question.
Soh et al. (2022) studied Sudden unexpected death in epilepsy (SUDEP). Rare SCN5A variants (p.V223G, p.I397V, p.R523C) and lamotrigine vs. Wild-type human NaV1.5 channels was evaluated on Human NaV1.5 channel function (activation, inactivation, recovery). Rare SCN5A variants significantly impacted human NaV1.5 channel function, and lamotrigine altered wild-type but not p.R523C channel inactivation, suggesting increased arrhythmogenic risk in SUDEP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: